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Abstract
Background: At the time of approval of a new medicine, there are few long-term data on the medicine’s benefit–risk
balance. Clinical trials are designed to demonstrate efficacy, but have major limitations with regard to safety in terms of
patient exposure and length of follow-up. This study of the number of patients who had been administered medicines at
the time of medicine approval by the European Medicines Agency aimed to determine the total number of patients studied,
as well as the number of patients studied long term for chronic medication use, compared with the International
Conference on Harmonisation’s E1 guideline recommendations.
Methods and Findings: All medicines containing new molecular entities approved between 2000 and 2010 were included
in the study, including orphan medicines as a separate category. The total number of patients studied before approval was
extracted (main outcome). In addition, the number of patients with long-term use (6 or 12 mo) was determined for chronic
medication. 200 unique new medicines were identified: 161 standard and 39 orphan medicines. The median total number of
patients studied before approval was 1,708 (interquartile range [IQR] 968–3,195) for standard medicines and 438 (IQR 132–
915) for orphan medicines. On average, chronic medication was studied in a larger number of patients (median 2,338, IQR
1,462–4,135) than medication for intermediate (878, IQR 513–1,559) or short-term use (1,315, IQR 609–2,420). Safety and
efficacy of chronic use was studied in fewer than 1,000 patients for at least 6 and 12 mo in 46.4% and 58.3% of new
medicines, respectively. Among the 84 medicines intended for chronic use, 68 (82.1%) met the guideline recommendations
for 6-mo use (at least 300 participants studied for 6 mo and at least 1,000 participants studied for any length of time),
whereas 67 (79.8%) of the medicines met the criteria for 12-mo patient exposure (at least 100 participants studied for
12 mo).
Conclusions: For medicines intended for chronic use, the number of patients studied before marketing is insufficient to
evaluate safety and long-term efficacy. Both safety and efficacy require continued study after approval. New epidemiologic
tools and legislative actions necessitate a review of the requirements for the number of patients studied prior to approval,
particularly for chronic use, and adequate use of post-marketing studies.
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Introduction
Clinical studies conducted during the development of new
medicines are generally designed to show efficacy under strict
conditions and are performed in relatively small and selected patient
populations [1,2]. The total number of patients exposed to a new
drug before approval is generally assumed to be approximately
1,000 patients [1,3]. However, to our knowledge, a scientific review
of the number of patients studied before European approval has
never been conducted. The number of patients exposed to a
medicine during trials before approval directly defines the level of
knowledge about the efficacy and adverse effects of the new
medicine in humans. If few patients have used the medicine before
approval, limited information on adverse effects will be available,
and the benefit–risk balance is hard to determine. For physicians
and other healthcare providers, it is of major importance to provide
evidence-based care in everyday practice, but they are often not
aware of these limitations. Therefore, the numbers of patients
studied before approval merits study, with particular attention to
medicines for chronic use.
Although guidelines on the number of patients to be studied are
in place, there are no formal European Union requirements for
study size and length of follow-up in studies prior to the approval
of new medicines. The size of an individual study and the total
clinical development programme are mainly, if not entirely, driven
by the statistical power needed to establish efficacy. The duration
of trials is also determined by the indication for which efficacy
must be proven and is rarely continued longer than strictly needed.
For the safety evaluation of medicines developed for chronic
treatment of non-life-threatening diseases, the European Medi-
cines Agency (EMA) and its United States counterpart, the Food
and Drug Administration, use guidance on patient exposure and
the length of time participants are studied based on the
International Conference on Harmonisation (ICH) E1 guideline
[4,5]. The E1 guideline sets recommendations on three levels: a
total patient exposure of at least 1,000 to 1,500 patients, 6 mo of
use by 300 patients, and 12 mo of use by 100 patients [4]. The
reasons for choosing 300 and 100 patients as the target numbers to
be studied for 6 and 12 mo are not provided in the ICH E1
guideline.
The aim of this study was to review the number of patients
exposed to new medicines before approval in the EU (main
outcome), with a special focus on long-term exposure for
medicines intended for chronic use.
Methods
The publicly available Community Register of Medicinal
Products of the European Commission was used to identify all
products approved in the EU through the ‘‘centralised procedure’’
between 1 January 2000 and 31 December 2010, including those
that were subsequently withdrawn or suspended [6]. We included
all unique, new active substances that were approved in this
period. Duplicate products were excluded. Duplicates were
defined as all medicines with an identical active substance, and
with the same dossier and the same preclinical and clinical studies,
but with two or more product names (e.g., Januvia and Xelevia).
European public assessment reports (EPARs) are publicly
available on the EMA’s website [7]. From the EPARs for all
products, we extracted the total number of participants in the
studies (patients as well as healthy volunteers) who received at least
one dose of the medicine. Data were read from automated records
of the European Commission [6] directly, and additional data
(number of participants) were extracted by R. G. D. These data
were systematically checked by M. L. D. B. to ensure accuracy or
to resolve uncertainties if numbers were not reported clearly.
The intended use of medications was assessed based on the
official indication at approval. With this indication as a reference,
intended treatment duration was classified as chronic, intermedi-
ate, or short term by R. G. D. and M. L. D. B. Any discrepancies
were resolved in discussion with A. d. B. Examples of chronic use
included asthma and HIV medication, intermediate length of use
included anticancer treatment, and short-term use included
antimicrobial medication and most analgesics and diagnostic
agents.
For all medicines intended for chronic use we extracted
additional information on the number of patients who had
received treatment for at least 6 mo and at least 12 mo. If no
(reliable) information on the number of exposed patients could be
obtained, patient exposure was categorised as missing. In some
EPARs the number of patients treated with the study medication
for 12 mo was reported, whereas use for at least 6 mo was not
reported. In such cases the number of participants with 12-mo use
was imputed as 6-mo use.
In addition, information was obtained on special authorisation
status (orphan status, exceptional circumstances, and conditional
approval) where applicable. Products were categorised as orphan
medicines if the EMA’s Committee for Orphan Medicinal
Products had granted them official EU orphan status; all other
medicines were categorised as ‘‘standard medicines’’.
Based on the total number of patients exposed before approval,
all products were divided into one of the following five groups: less
than 500 patients, 500 to 1,000 patients, 1,000 to 2,000 patients,
2,000 to 5,000 patients, and more than 5,000 patients. To assess
long-term use before approval, the numbers of participants studied
for at least 6 mo and for at least 12 mo were calculated. The cutoff
values used for the number of patients required in long-term
studies were chosen according to the clinical safety guideline: at
least 300 for 6-mo use and at least 100 for 12-mo use [4,5].
The non-parametric Wilcoxon two-sample test was used to
determine whether there was a statistically significant difference in
the number of participants studied for medicines still on the
market versus those withdrawn from the market as of 4 November
2011.
Results
We identified 200 newly approved medicines in the period
2000–2010, of which 161 were standard (non-orphan) medicines
(80.5%) and 39 were official orphan medicines (19.5%). The
specific medicines and number of patients studied are listed in
Dataset S1.
Total Number of Patients Studied
The median number of total patients studied per medicine was
1,708 (interquartile range [IQR] 968–3,195) for standard medi-
cines and 438 (IQR 132–915) for orphan medicines (Figure 1).
Orphan medicines generally had small numbers of patients in
clinical studies; 31 (79.5%) of the products had been used by fewer
than 1,000 patients. Eight orphan medicines had been tested in
more than 1,000 patients (plerixafor, mecasermin, rufinamide,
trabectedin, sorafenib, ziconotide, anagrelide, and imatinib).
Among the standard medicines, 90 (55.9%) of the 161 products
had been studied in fewer than 2,000 patients in total, of which 20
(13.7%) were studied in fewer than 500. 52 (32.3%) products were
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studied in 2,000–5,000 patients, and 19 (11.8%) were studied in
more than 5,000 (Table 1).
The number of patients receiving medicines for short-term
treatment before marketing authorisation varied considerably.
Eight (16.0%) medicines had been studied in fewer than 500
patients, whereas five (10.0%) medicines had been studied in more
than 5,000 patients, and 13 (26.0%) in 2,000–5,000 patients.
Medicines intended for intermediate length of use were tested on
the smallest number of patients before approval; 25 (92.4%)
medicines were used by fewer than 2,000 patients. Within this
category, 20 (74.1%) medicines were indicated for treatment of
cancer. Medicines for chronic use were studied in larger numbers
of patients during clinical development. In total, 51 (60.7%) of
these products had been used by 2,000 or more patients, of which
13 (15.1%) had been studied in more than 5,000 patients.
Six medicines in our analyses had their marketing authorisation
subsequently suspended or withdrawn. Medicines still on the
market had been studied before approval in a median 1,694
patients (IQR 899–3,167), versus 2,161 patients (IQR 968–5,479)
for suspended or withdrawn medicines; this difference was not
statistically significant (p=0.61; Wilcoxon two-sample test).
Long-Term Studies of Medicines for Chronic Use
Among the 84 medicines intended for chronic use, 69 (82.1%)
met the patient exposure recommendations for 6-mo use (at least
300 participants studied for 6 mo and at least 1,000 participants in
total), and 67 (79.8%) of the medicines met the criteria for 12-mo
patient exposure (at least 100 participants) (Table 2; Figure 2).
Safety and efficacy of chronic use were studied in fewer than
1,000 individuals for 6 mo or more in 41 (48.8%) medicines, and
for 12 mo or more in 49 (58.3%) medicines.
Six (7.1%) medicines had been used by fewer than 300 patients
for a minimum of 6 mo. 33 (39.3%) medicines had been tested in
300 to 1,000 patients, and 39 (46.4%) medicines had been tested in
more than 1,000 patients, both for a minimum of 6 mo. For six
(7.1%) medicines, information on the number of patients included
in long-term studies was missing in the EPAR.
For 45 (53.6%) medicines, 100 to 1,000 patients had been
studied for at least 12 mo, and 25 (29.8%) products had been
studied in over 1,000 patients. For four medicines (4.8%), fewer
than 100 patients had been studied for at least 12 mo. Data on 12-
mo use was missing in 10 (11.9%) EPARs.
Discussion
To our knowledge no recent research has systematically assessed
the number of patients and volunteers exposed to new medicines
before approval. A previous study of product licence applications
in the UK between 1987 and 1989 by Rawlins and Jefferys showed
that the median number of individuals exposed to new active
substances in premarketing studies was 1,480 (range 129–9,400)
for successful applications, and 1,052 (range 43–15,962) for
unsuccessful applications [8]. The proportion of withdrawals after
approval in our study was comparable to that in the previous UK
study. In contrast to the study by Rawlins and Jefferys, our study
was restricted to successful applications, but study size has
increased only marginally since the late 1980s. For both policy
makers and healthcare providers, it is important to be aware of the
inherent limitations of the size of trials conducted before approval
with regard to efficacy as well as adverse effects.
The aim of the ICH E1 guideline on data requirements for
medicines for long-term use is to assure at least a minimum of
experience and knowledge of long-term efficacy and safety before
approval. Overall, 1,000 to 1,500 patients in total, and a minimum
of 300 and 100 treated for at least 6 and 12 mo, respectively, are
required. Results from our study show that the minimal
requirements are met by approximately 80% of new medicines
approved for chronic use in the EU.
Although increasing the number of patients exposed to a
medicine before approval could be justified, especially for
medicines intended for long-term use, the requirement could
delay new products entering the market. In the current era, in
which patients and healthcare providers demand more rapid
access to new medicines, this would not be acceptable for most
stakeholders in the field. Furthermore, randomised controlled
trials sufficiently large to accurately assess long-term safety and
effectiveness are expensive, and epidemiological studies in the
post-marketing phase may be more suitable.
As an example, in the meta-analysis by Nissen and Wolski
published in 2007 on myocardial infarction in users of rosiglita-
zone, myocardial infarction incidence was approximately 36 per
10,000 patients in the control group, with rosiglitazone use
incurring an estimated increased risk (odds ratio) of 1.43 [9]. This
meta-analysis contributed much to the US Food and Drug
Administration’s decision to update the labelling and restrict the
prescription of rosiglitazone-containing products [10]. In the EU,
it led the EMA to formally suspend the marketing authorisation of
rosiglitazone-containing products.
For a clinical trial to reveal a relative risk of 1.43 with statistical
significance (a power of 80% and a of 0.05%, see Table 3),
approximately 30,000 patients per study arm would be required,
necessitating a total study size of 60,000 patients. Such large trials
would be difficult to conduct before approval, and meta-analyses
or observational studies are more feasible for studying such
outcomes.
However, for chronic medications, the clinical safety guidelines
require too few patients to be studied long term. The possibility of
detecting long-term adverse events from follow-up of only 300
patients for 6 mo or 100 patients for 12 mo, as required in the
current ICH E1 guideline, is insufficient. It would be more sensible
to move towards a minimum targeted long-term study size of
1,000 to 1,500 patients, comparable to the overall study size now
required [4].
Knowledge of a medicine’s benefit–risk profile, including its
effectiveness in clinical practise and associated adverse effects,
should only increase over time and with increasing use. Clinical
use outside the restrictive environment of trials may be the only
way to achieve a full understanding of the safety profile [3,11–13].
Pharmacovigilance activities involving active monitoring of
spontaneous reporting systems, registries, post-marketing safety
studies, and risk management plans (RMPs), have proven to be
important tools in facilitating this process [14,15]. Spontaneous
adverse event reporting has been the main source of information
in pharmacovigilance for decades, but it has important limitations.
To be of value, spontaneous reporting requires healthcare
providers and patients to notice and report the adverse effect
[1]. This is possible for rare adverse effects, but cannot be done for
common morbidities with a long time to disease onset [1,15–19].
New methods are employed in the US Food and Drug
Administration Sentinel Initiative [20,21] and EU EU-ADR
project [22] to signal such adverse effects and address these
problems. Both projects aim to use anonymised automated
healthcare records to continuously monitor medicines for the
disproportionate occurrence of adverse events [23–25].
RMPs have become an important tool to progressively extend
the knowledge of the safety of newly approved medicines [26,27].
International guidance on RMPs has been established (ICH E2E
guideline ‘‘Pharmacovigilance Planning’’) [28] and adopted in
Exposure to Medicines Prior to Approval
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European law in 2005 [29]. With RMPs, pharmacovigilance has
passed a turning point, moving from a largely reactive role to a
continuous proactive risk management approach. Now, the
demonstration of safety in practice and the process of filling in
gaps in knowledge after marketing have been added to the passive
monitoring of case reports [15]. An RMP serves as the central
Figure 1. Boxplots with medians of the number of patients studied before approval. Results for standard (non-orphan) medicines are
presented by intended length of use of the products (chronic, intermediate, or short-term) and as one group (sub-total). Boxplots present the 50th
percentile, i.e., the median value is given, with the interquartile range (25th and 75th percentiles) indicated by the box, the 2nd and 98th percentiles
indicated by the horizontal bars of the whiskers, and outliers indicated by individual circles. The total number of patients studied (y-axis) is plotted on
a logarithmic scale.
doi:10.1371/journal.pmed.1001407.g001
Table 1. Number (percent) of medicines categorised according to total number of individuals studied prior to marketing.
Total Number of
Patients Standard Medicines Orphan Medicines Total
Chronic Intermediate Short-Term Sub-Total
,500 6/84 (7.1%) 6/27 (22.2%) 8/50 (16.0%) 20/161 (12.4%) 21/39 (53.8%) 41/200 (20.5%)
500–1,000 4/84 (4.8%) 9/27 (33.3%) 10/50 (20.0%) 23/161 (14.3%) 10/39 (25.6%) 33/200 (16.5%)
1,000–2,000 23/84 (27.4%) 10/27 (37.0%) 14/50 (28.0%) 47/161 (29.2%) 7/39 (17.9%) 54/200 (27.0%)
2,000–5,000 38/84 (45.2%) 1/27 (3.7%) 13/50 (26.0%) 52/161 (32.3%) 1/39 (2.6%) 53/200 (26.5%)
.5,000 13/84 (15.5%) 1/27 (3.7%) 5/50 (10.0%) 19/161 (11.8%) 0/39 (0.0%) 19/200 (9.5%)
Total 84/84 (100%) 27/27 (100%) 50/50 (100%) 161/161 (100%) 39/39 (100%) 200/200 (100%)
Percentages are column percentages.
doi:10.1371/journal.pmed.1001407.t001
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Table 2. Number (percent) of medicines categorised according to total number of individuals studied for 6 and 12 mo (long term)
prior to marketing.
Total Number of Patients Number of Patients with 6-mo Use Number of Patients with 12-mo Use
,300 300–1,000 .1,000 Missing ,100 100–1,000 .1,000 Missing
,1,000 (n= 10) 3/10 (30.0%) 3/10 (30.0%) 0/10 (0.0%) 4/10 (40.0%) 1/10 (10.0%) 3/10 (30.0%) 0/10 (0.0%) 6/10 (60.0%)
1,000–5,000 (n= 61) 2/61 (3.3%) 30/61 (49.2%) 28/61 (45.9%) 1/61 (1.6%) 3/61 (4.9%) 39/61 (63.9%) 16/61 (26.2%) 3/61 (4.9%)
.5,000 (n= 13) 1/13 (7.7%) 0/13 (0.0%) 11/13 (84.6%) 1/13 (7.7%) 0/13 (0.0%) 3/13 (23.1%) 9/13 (69.2%) 1/13 (7.7%)
Total (n= 84) 6/84 (7.1%) 33/84 (39.3%) 39/84 (46.4%) 6/84 (7.1%) 4/84 (4.8%) 45/84 (53.6%) 25/84 (29.8%) 10/84 (11.9%)
Percentages presented are row percentages for 6 and 12 mo use. Products with (1) a total number of patients studied of fewer than 1,000, (2) fewer than 300 studied for
6 mo, or (3) fewer than 100 studied for 12 mo do not meet the guideline criteria, and are shown in bold. For purposes of calculation and display, missing data were
assumed to be in compliance with the recommended patient exposures.
doi:10.1371/journal.pmed.1001407.t002
Figure 2. Scatterplot displaying the total number of patients studied before approval plotted against the number of patients
studied long term (for 6 and 12 mo) for chronic medication. Reference lines are added to indicate the minimum criteria from the ICH E1
guideline: 1,000 patients in total and 300 and 100 patients studied for 6 and 12 mo, respectively. Any products not meeting the ICH E1 guideline
recommendations are shown in red.
doi:10.1371/journal.pmed.1001407.g002
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document in pharmacovigilance activities for an individual
product, and contains three elements: (1) a safety specification
describing the potential and identified risks as well as important
missing information on adverse effects, (2) the pharmacovigilance
plan, which describes proposals to acquire more data on possible
risks, identified risks, and missing information, and (3) the risk
minimisation plan [28,30]. RMPs are prepared and maintained by
the pharmaceutical companies, but require approval by regulatory
authorities, who may require companies to add new risks to the
RMP or to initiate new risk minimisation activities, including new
studies for safety or efficacy. The newest EU legislation requires a
summary of the RMP to be made public [30].
Post-marketing observational pharmacoepidemiological studies
are essential, even though confounding in observational data may
be impossible to eliminate completely. RMPs and other pharma-
covigilance activities do not overcome the problems due to
insufficient statistical power and the need for large study sizes to
detect less common adverse effects in clinical trials (as discussed
above for the case of rosiglitazone). Signals of adverse effects
require formal and adequately powered observational studies
before the issue can be quantified and addressed.
Regulator-driven post-marketing studies are possible in both the
US [31,32] and EU (called post-authorisation safety studies in
RMPs) [33,34]. In the US, the effectiveness of post-marketing
studies was reviewed several years ago, and the review indicated
that pharmaceutical companies often progress slowly if at all in
initiating, continuing, and completing such studies [15,16]. For the
EU situation, such a detailed review has not been conducted, but a
review by the EMA itself indicated that studies progressed well
[35]. However, this review considered the initiation of a study as
progress, rather than considering how much time was spent before
finalisation. The European pharmacovigilance legislation adopted
in December 2010 provides an important new legal basis to
overcome these problems and makes it possible to impose
requirements for post-authorisation safety studies on pharmaceu-
tical companies when needed [33,34,36].
Recently, new approaches in regulation have been proposed by
means of ‘‘adaptive licensing’’ [37,38]. In adaptive licensing, the
regulatory outcome (either rejection or approval of a new medicine)
is changed to a process in which requirements for first approval are
less strict, but research must continue after approval, and marketing
authorisation continuation is dependent on the results. Such an
approach could solve limitations in current regulatory practice, as it
is expected to provide better data on product effectiveness in real
world clinical practice, rather than only efficacy in clinical trials
[39]. Furthermore, observational studies on adverse effects could
then become a formal part of the approval dossier. In addition to
classical observational study designs, new study methods could
provide new tools to further analyse safety [40].
A re-evaluation of the requirements regarding study size and
long-term data for approval of new medicines seems to be merited.
Such a discussion should involve healthcare providers, patients,
and academia, as well as industry and regulators, and should
include debate on the level of acceptable uncertainty, especially for
adverse events and the long-term outcomes for chronic medica-
tion.
The numbers of individuals studied before approval of new
medicines in Europe from 2000 to 2010 are comparable to the
study sizes for medicines approved in UK in the 1980s, and are
generally adequate to assess only short-term efficacy. For most
approved medicines intended for chronic use, the number of
patients studied before marketing is insufficient to study safety and
long-term efficacy. In light of new scientific and legislative tools to
monitor benefits and risks in clinical use, discussion of the long-
term exposure requirements for approval of medicines, particu-
larly for medicines intended for chronic use, seems warranted.
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Editors’ Summary
Background. Before any new medicine is marketed for the
treatment of a human disease, it has to go through extensive
laboratory and clinical research. In the laboratory, scientists
investigate the causes of diseases, identify potential new
treatments, and test these interventions in disease models,
some of which involve animals. The safety and efficacy of
potential new interventions is then investigated in a series of
clinical trials—studies in which the new treatment is tested
in selected groups of patients under strictly controlled
conditions, first to determine whether the drug is tolerated
by humans and then to assess its efficacy. Finally, the results
of these trials are reviewed by the government body
responsible for drug approval; in the US, this body is the
Food and Drug Administration, and in the European Union,
the European Medicines Agency (EMA) is responsible for the
scientific evaluation and approval of new medicines.
Why Was This Study Done? Clinical trials are primarily
designed to test the efficacy—the ability to produce the
desired therapeutic effect—of new medicines. The number
of patients needed to establish efficacy determines the size
of a clinical trial, and the indications for which efficacy must
be shown determine the trial’s duration. However, identify-
ing adverse effects of drugs generally requires the drug to be
taken by more patients than are required to show efficacy, so
the information about adverse effects is often relatively
limited at the end of clinical testing. Consequently, when
new medicines are approved, their benefit–risk ratios are
often poorly defined, even though physicians need this
information to decide which treatment to recommend to
their patients. For the evaluation of risk or adverse effects of
medicines being developed for chronic (long-term) treat-
ment of non-life-threatening diseases, current guidelines
recommend that at least 1,000–1,500 patients are exposed to
the new drug and that 300 and 100 patients use the drug for
six and twelve months, respectively, before approval. But are
these guidelines being followed? In this database analysis,
the researchers use data collected by the EMA to determine
how many patients are exposed to new medicines before
approval in the European Union and how many are exposed
for extended periods of time to medicines intended for
chronic use.
What Did the Researchers Do and Find? Using the
European Commission’s Community Register of Medicinal
Products, the researchers identified 161 standard medicines
and 39 orphan medicines (medicines to treat or prevent rare
life-threatening diseases) that contained new active sub-
stances and that were approved in the European Union
between 2000 and 2010. They extracted information on the
total number of patients studied and on the number
exposed to the medicines for six months and twelve months
before approval of each medicine from EMA’s European
public assessment reports. The average number of patients
studied before approval was 1,708 for standard medicines
and 438 for orphan medicines (marketing approval is easier
to obtain for orphan medicines than for standard medicines
to encourage drug companies to develop medicines that
might otherwise be unprofitable). On average, medicines for
chronic use (for example, asthma medications) were studied
in more patients (2,338) than those for intermediate use such
as anticancer drugs (878), or short-term use such as
antibiotics (1,315). The safety and efficacy of chronic use
was studied in fewer than 1,000 patients for at least six and
twelve months in 46.4% and 58.4% of new medicines,
respectively. Finally, among the 84 medicines intended for
chronic use, 72 were studied in at least 300 patients for six
months, and 70 were studied in at least 100 patients for
twelve months.
What Do These Findings Mean? These findings suggest
that although the number of patients studied before
approval is sufficient to determine the short-term efficacy
of new medicines, it is insufficient to determine safety or
long-term efficacy. Any move by drug approval bodies to
require pharmaceutical companies to increase the total
number of patients exposed to a drug, or the number
exposed for extended periods of time to drugs intended for
chronic use, would inevitably delay the entry of new
products into the market, which likely would be unaccept-
able to patients and healthcare providers. Nevertheless, the
researchers suggest that a reevaluation of the study size and
long-term data requirements that need to be met for the
approval of new medicines, particularly those designed for
long-term use, is merited. They also stress the need for
continued study of both the safety and efficacy of new
medicines after approval and the importance of post-
marketing studies that actively examine safety issues.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001407.
N The European Medicines Agency (EMA) provides informa-
tion about all aspects of the scientific evaluation and
approval of new medicines in the European Union; its
European public assessment reports are publicly available
N The European Commission’s Community Register of
Medicinal Products is a publicly searchable database of
medicinal products approved for human use in the
European Union
N The US Food and Drug Administration provides informa-
tion about drug approval in the US for consumers and for
health professionals
N The US National Institutes of Health provides information
(including personal stories) about clinical trials
Exposure to Medicines Prior to Approval
PLOS Medicine | www.plosmedicine.org 8 March 2013 | Volume 10 | Issue 3 | e1001407
